| Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors (NCT07170293) | Tianjin Medical University Second Hospital | 2027-08-31 |
| Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC (NCT07749924) | Tianjin Medical University Second Hospital | 2026-08-10 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer (NCT07756008) | Tianjin Medical University Second Hospital | 2026-08-01 |
| Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive (NCT07712029) | Tianjin Medical University Second Hospital | 2026-08-01 |
| Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? (NCT07625527) | Tianjin Medical University Second Hospital | 2026-05-30 |
| Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer (NCT07475403) | Tianjin Medical University Second Hospital | 2026-03-16 |
| Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma (NCT07441499) | Tianjin Medical University Second Hospital | 2026-03-01 |
| Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma (NCT07697417) | Tianjin Medical University Second Hospital | 2026-01-01 |
| Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer (NCT07233252) | Tianjin Medical University Second Hospital | 2025-11-25 |
| Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous Nephrolithotomy for Staghorn Calculi (NCT07172373) | Tianjin Medical University Second Hospital | 2025-10-01 |
| Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer (NCT07187635) | Tianjin Medical University Second Hospital | 2025-09-28 |
| Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) (NCT07179783) | Tianjin Medical University Second Hospital | 2025-09-22 |
| Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer (NCT07180212) | Tianjin Medical University Second Hospital | 2025-09-20 |
| The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer (NCT07130578) | Tianjin Medical University Second Hospital | 2025-09-01 |
| Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC) (NCT07321210) | Tianjin Medical University Second Hospital | 2025-09-01 |
| Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC) (NCT07321197) | Tianjin Medical University Second Hospital | 2025-09-01 |
| Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC (NCT07172386) | Tianjin Medical University Second Hospital | 2025-07-31 |
| Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC (NCT07126119) | Tianjin Medical University Second Hospital | 2025-07-05 |
| Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer (NCT07125547) | Tianjin Medical University Second Hospital | 2025-07-05 |
| Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) (NCT06895733) | Tianjin Medical University Second Hospital | 2024-11-27 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395) | Tianjin Medical University Second Hospital | 2024-11-01 |
| RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure (NCT06663007) | Tianjin Medical University Second Hospital | 2024-09-24 |
| Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis (NCT06536725) | Tianjin Medical University Second Hospital | 2024-06-01 |
| Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma (NCT07657325) | Tianjin Medical University Second Hospital | 2024-04-01 |
| Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma (NCT06031636) | Tianjin Medical University Second Hospital | 2023-07-20 |
| Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors (NCT06022289) | Tianjin Medical University Second Hospital | 2023-05-01 |
| Study on the Influencing Factors of Electroencephalogram Parameters Under Anesthesia (NCT04760028) | Tianjin Medical University Second Hospital | 2023-03-01 |
| Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) (NCT05837806) | Tianjin Medical University Second Hospital | 2022-12-30 |
| Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors (NCT06022276) | Tianjin Medical University Second Hospital | 2022-12-01 |
| Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer (NCT06009848) | Tianjin Medical University Second Hospital | 2022-10-10 |
| DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors (NCT06009835) | Tianjin Medical University Second Hospital | 2022-08-07 |
| Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC (NCT05485896) | Tianjin Medical University Second Hospital | 2022-07-01 |
| Tislelizumab Plus Lenvatinib in Stage III-IV RCC (NCT05485883) | Tianjin Medical University Second Hospital | 2022-07-01 |
| A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma (NCT05220124) | Tianjin Medical University Second Hospital | 2022-01-05 |
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study (NCT05418309) | Tianjin Medical University Second Hospital | 2021-12-27 |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study (NCT05328336) | Tianjin Medical University Second Hospital | 2021-11-11 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma (NCT05030077) | Tianjin Medical University Second Hospital | 2021-10-01 |
| Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma (NCT04995016) | Tianjin Medical University Second Hospital | 2021-08-20 |
| A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer (NCT04958473) | Tianjin Medical University Second Hospital | 2021-08-01 |
| Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable (NCT05495724) | Tianjin Medical University Second Hospital | 2021-07-23 |
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable (NCT04730232) | Tianjin Medical University Second Hospital | 2020-12-27 |
| MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors (NCT06030869) | Tianjin Medical University Second Hospital | 2020-12-01 |
| Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer (NCT04486287) | Tianjin Medical University Second Hospital | 2020-09-01 |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） (NCT04659785) | Tianjin Medical University Second Hospital | 2020-07-01 |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor (NCT04179656) | Tianjin Medical University Second Hospital | 2019-12-01 |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer (NCT04101812) | Tianjin Medical University Second Hospital | 2019-09-17 |
| Treatment of Carrying TP53 Harmful Mutations (NCT03645200) | Tianjin Medical University Second Hospital | 2019-07-01 |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency (NCT03580239) | Tianjin Medical University Second Hospital | 2019-01-01 |
| Selective Treatment According to Molecular Subtype of Prostate Cancer (NCT03696186) | Tianjin Medical University Second Hospital | 2018-08-01 |
| Advanced Refractory Solid Tumors With TP53 Mutations Register Study (NCT03927599) | Tianjin Medical University Second Hospital | 2018-08-01 |
| Imaging-Guided Classification for Endophytic Renal Tumors: PN Strategies & Outcomes (NCT06954571) | Tianjin Medical University Second Hospital | 2018-01-01 |